Media Release

6 November 2024

Syntara selected for oral presentation at ASH to present interim Phase 2 blood cancer trial data

Clinical stage drug development company Syntara Limited (ASX: SNT) is pleased to announce that its abstract[1] has been has been selected for an oral presentation at the American Society of Haematology meeting (ASH) where interim results from its Phase 2 trial evaluating SNT-5055, in combination with ruxolitinib to treat the bone marrow cancer myelofibrosis, will be presented.

ASH takes place from 7-10 December 2024 in San Diego and is the largest haematology scientific conference held globally, attended by over 30,000 scientists, clinicians, companies and investors from more than 100 countries.

Abstracts for this year's ASH Meeting and Exposition were made available earlier today, with a record-breaking number of abstracts submitted and more than 7,950 accepted.

Syntara's abstract has been identified as one of a select group to be given an oral presentation, scheduled for 5:30pm PT on 9 December 2024.

This oral presentation will contain updated efficacy and safety data including 3-month data from all patients in the study, as well as data from patients that have completed 6 and 9 months of treatment.

The abstract published today contains baseline information on the current study in myelofibrosis, where patients treated with SNT-5505 on top of a JAK inhibitor (ruxolitinib) for a period of 12 months. Key points in the poster include:

- As of 31 of July 2024, planned enrolment was completed with 15 pts (median age 72 years).
- All patients were classified as intermediate or high risk at entry to the study with a median time since myelofibrosis diagnosis of approximately 5 years and a median ruxolitinib treatment duration of approximately 2 years.
- The majority of patients entering the study were symptomatic (median MF-SAF TSS of 22.5) and had enlarged spleens (median volume was 1353 cm^3).

Syntara's CEO Gary Phillips commented: "It was pleasing to see the importance and relevance of this interim data update recognised by selection for a highly prized oral presentation. We will seek a meeting with the FDA in 1H 2025 to discuss the next steps in the clinical development program once we have enough data to fully characterise the safety and efficacy profile of the drug.

Reference 1: 1001 Multicenter, Open-Label Phase 1/2a Study of Pxs-5505 and Ruxolitinib in Patients with Primary, Post-Polycythemia Vera (PV) or Post-Essential Thrombocythemia (ET) Myelofibrosis

#ENDS#

SOURCE:
Syntara Limited (ASX: SNT),
Sydney, Australia
(ABN: 75 082 811 630)

AUTHORISED FOR RELEASE TO ASX BY:
Syntara Limited Disclosure Committee.
Contact: David McGarvey, Company Secretary:

+61 2 8760 1480
david.mcgarvey@syntaraTX.com.au

CONTACT:

Syntara investor / media relations:
Matthew Wright
NWR Communications
+61 451 896 420
matt@nwrcommunications.com.au

JOIN THE SYNTARA MAILING LIST HERE

About Syntara

Syntara Limited (ABN: 75 082 811 630) is a clinical stage drug development company targeting extracellular matrix dysfunction with its world-leading expertise in amine oxidase chemistry and other technologies to develop novel medicines for blood cancers and conditions linked to inflammation and fibrosis.

Syntara is managing three phase 2 clinical studies in diseases of high unmet need with a further two potential phase 1c/2 studies being evaluated for 2024. Lead candidate SNT-5505 is for the bone marrow cancer myelofibrosis which causes a build-up of scar tissue that leads to loss of red and white blood cells and platelets. SNT-5505 has already achieved FDA Orphan Drug Designation and clearance under an Investigational New Drug Application for development in myelofibrosis. After encouraging phase 2a trial results when used as a monotherapy in myelofibrosis, SNT-5505 is now being studied with a JAK inhibitor in a further phase 2 myelofibrosis study with interim data by Q4 2024. Protocols for another two phase 1c/2 studies with SNT-5505 in patients with a blood cancer called myelodysplastic syndrome are in development and expected to commence recruitment by Q1 2025.

Syntara is also advancing both oral and topical pan-LOX inhibitors in scar prevention and scar modification programs as part of an ongoing collaboration with Professor Fiona Wood and the University of Western Australia. SNT-4728 is being studied in collaboration with Parkinson's UK as a best-in-class SSAO/MAOB inhibitor to treat sleep disorders and slow progression of neurodegenerative diseases like Parkinson's by reducing neuroinflammation.

Other Syntara drug candidates target fibrotic and inflammatory diseases such as kidney fibrosis, NASH, pulmonary fibrosis and cardiac fibrosis.

Syntara developed two respiratory products available in world markets (Bronchitol® for cystic fibrosis and Aridol®- a lung function test), which it sold in October 2023.

Syntara is listed on the Australian Securities Exchange, code SNT. The company's management and scientific discovery team are based in Sydney, Australia. www.syntaraTX.com.au.

Forward-Looking Statements

Forward-looking statements in this media release include statements regarding our expectations, beliefs, hopes, goals, intentions, initiatives or strategies, including statements regarding the potential of products and drug candidates. All forward-looking statements included in this media release are based upon information available to us as of the date hereof. Actual results, performance or achievements could be significantly different from those expressed in, or implied by, these forward-looking statements. These forward-looking statements are not guarantees or predictions of future results, levels of performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results to differ materially from those expressed in the statements contained in this document. For example, despite our efforts there is no certainty that we will be successful in partnering any of the products in our pipeline on commercially acceptable terms, in a timely fashion or at all. Except as required by law we undertake no obligation to update these forward-looking statements as a result of new information, future events or otherwise.